Remedium Lifecare Ltd, a Mumbai-based pharmaceutical company, is embarking on a transformative journey by significantly strengthening its Contract Development and Manufacturing Organization (CDMO) and Research & Development (R&D) infrastructure. The goal? To evolve from a pharmaceutical trader into a fully integrated pharmaceutical solutions provider with a global reach.

The company is directing its focus toward building a strong footprint in the UK and Europe, supported by facility upgrades, technological integration, and green chemistry innovation.

₹182.7 Crore Export Deal Secured

The major breakthrough in Remedium's global strategy came with the announcement of a ₹182.7 crore multi-year export contract with a leading pharmaceutical distributor in the UK and Europe. This marks a significant leap for the company as it establishes itself on the international pharmaceutical map.

This contract validates Remedium’s enhanced manufacturing and testing capabilities, and reflects global confidence in its revamped business model.

What Does the CDMO Upgrade Involve?

Although no new manufacturing capacity is being added, the CDMO upgrade introduces dedicated infrastructure for quality control and testing, specifically:

• Advanced testing equipment for validating inbound and outbound materials

• Expanded lab space for product development and R&D

• Dedicated CDMO infrastructure for international client projects

These steps will improve operational efficiency, facilitate backward integration, and accelerate the development of pharmaceutical products and intermediates, positioning Remedium as a reliable global partner.

Statement from Leadership

Mr. Adarsh Munjal, Whole Time Director of Remedium Lifecare Ltd, stated:

“Our focus is to build a robust foundation for CDMO and R&D services that will position Remedium to secure new contracts, drive innovation, and improve margins through backward integration.”

The facility’s new capabilities will support international project execution, allowing Remedium to meet customer-specific quality standards without being restricted by USFDA or EU regulatory requirements for regulated markets. This flexibility enhances the company’s speed-to-market in new geographies.

Strong Response to Rights Issue

As of the 8th day of the rights issue, Remedium received a near 50% subscription, collecting ₹24.27 crore out of a targeted ₹24.28 crore, with each share priced at ₹1. The rights issue closes on May 14, 2025, with the renunciation window running from April 30 to May 9, 2025.

This funding is crucial to support the CDMO infrastructure upgrade and enhance research and testing capabilities. It also reflects strong investor confidence in Remedium’s strategic pivot.

Green Chemistry Innovation through JiyaYu Lifesciences

To further enhance its sustainability profile, Remlife Global PTE Ltd (Remedium's Singapore-based subsidiary) has partnered with JiyaYu Lifesciences, a platform that pioneers green chemistry technologies.

This collaboration will enable Remlife Global to:

• Replace animal-origin raw materials in API manufacturing

• Use bioprocesses that are sustainable, cost-effective, and regulatory compliant

• License fully developed technologies from JiyaYu

• Scale and commercialize these innovations at GMP-compliant sites

This initiative places Remedium at the forefront of ethical and environmentally responsible pharma manufacturing.

Strategic Outlook

Remedium’s evolution is not just a business shift—it’s a long-term strategic transformation aimed at:

• Building value-accretive assets

• Improving client retention

• Enhancing margins through innovation

• Strengthening its position as a diversified pharmaceutical partner

The company’s multi-pronged approach—rights issue funding, CDMO & R&D upgrades, and global partnerships—lays the groundwork for a resilient and innovative business model.

Conclusion

Remedium Lifecare is on a strong growth trajectory, backed by smart capital deployment, technological investments, and a clear global vision. The company’s focus on testing, quality control, innovation, and sustainability is paving the way for long-term international success in a rapidly evolving pharmaceutical landscape.

Investors, partners, and clients can expect Remedium to emerge as a key player in global pharma services, with a unique blend of cost-efficiency, quality control, and ethical manufacturing.

The Upcoming IPOs in this week and coming weeks are Integrity Belrise Industries, Accretion Pharmaceuticals, Wagons Learning.

The Current active IPO are Integrity Infrabuild Developers, Virtual Galaxy Infotech.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.